Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...

针对慢性髓性白血病（CML）口服治疗药物TERN-701的CARDINAL研究已于2025年1月完成剂量递增阶段。剂量扩展阶段计划于2025年第二季度开始。初步数据显示出强有力的分子反应和良好的安全性特征。更多安全性和有效性数据预计将于2025年第四季度公布。据InvestingPro报道，六位分析师已上调了公司未来期间的盈利预期，表明对公司产品管线的信心不断增强。

Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) is expected to release its earnings data before the market opens on ...

Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (NASDAQ: TERN).

Terns Pharmaceuticals reported a strong financial position, with a cash balance of $373 million as of Q3 2024. InvestingPro analysis reveals that the company holds more cash than debt on its ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), ...

FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...

The initial tolerability data suggests potential upside to the safety profile, which could be a key differentiator in the crowded obesity treatment market. Terns Pharmaceuticals reported a strong ...

Terns Pharmaceuticals ( (TERN)) has issued an announcement. On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew Gengos as Chief Financial Officer, effective February 24 ...

Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing small-molecule therapies for serious diseases, announced the appointment of Andrew Gengos as its new chief financial ...